一分钟看懂
这是一项关于肺癌的I 期 / II 期研究，登记的药物或干预包括Obrixtamig；Pumitamig；Carboplatin；Etoposide，当前状态为尚未开始招募。登记地点显示中国成都、哈尔滨、上海有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Obrixtamig；Pumitamig；Carboplatin；Etoposide · I 期 / II 期
登记条件中文摘要
年龄范围：18岁及以上
登记的基本范围为不限性别，年龄18岁及以上；以下仅摘录8项专业入选条件，需结合英文原文并由研究团队确认。
登记摘要未单独列出可展示的排除条件，请查看英文原文并向研究团队确认。
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Sichuan Cancer Hospital · 成都
- Harbin Medical University Cancer Hospital · 哈尔滨
- Shanghai Chest Hospital · 上海
入选条件原文摘录
以下为摘录，请打开原始登记查看完整入排标准。
- Inclusion criteria:
- 1. Signed and dated written informed consent in accordance with ICH-GCP and local legislation prior to any trial-specific procedures, sampling, or analyses.
- 2. Male or female participants ≥18 years old and at least at the legal age of consent in countries where it is greater than 18 years at the time of signature of the Informed Consent Form (ICF).
- 3. Willing and able to comply with scheduled visits, treatment schedule, the planned trial assessments, laboratory tests, restrictions regarding prohibited medications, lifestyle restrictions, and other requirements related to the trial. This includes that they are able to understand and follow trial-related instructions.
- 4. Histologically or cytologically confirmed Extensive Stage Small Cell Lung Carcinoma (ES-SCLC) \[using the AJCC (American Joint Committee on Cancer) tumour node metastasis staging system combined with Veterans Administration Lung Study Group (VALG)'s two stage classification scheme\].
- 5. Prior systemic anti-cancer treatment for ES-SCLC:
- For Cohort 1
- must have received at least one line of platinum-containing treatment but no more than 2 lines of treatment per local standard of care for the treatment of ES-SCLC.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07843940；登记信息更新于 2026-09-30；本站同步于 2026-10-08。